Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1971 Jun;25(2):298–305. doi: 10.1038/bjc.1971.38

The Variability of Individual Tolerance to Methotrexate in Cancer Patients

H H Hansen, O S Selawry, J F Holland, C B McCall
PMCID: PMC2008449  PMID: 4256007

Abstract

Individual tolerance to single or widely spaced doses of methotrexate was explored in 49 patients with advanced cancer with normal serum creatinine and/or blood urea nitrogen. Methotrexate was given as an intravenous infusion over 1 hour at initial doses of 80-120 mg./m2 body surface area. The doses were increased by 50% increments every 2 weeks until moderate toxicity occurred, arbitrarily defined as leukopenia <5000/mm.3, and/or thrombocytopenia <100,000/mm.3, and/or the appearance of oral mucous or intestinal toxicity.

The individual dose required to produce initial evidence of toxicity varied by a factor of 18 between 50 and 900 mg./m2. Starting doses above 80 mg./m2 were potentially hazardous. Dose limiting toxicity consisted of leukopenia with or without stomatitis in 81% of the patients, and stomatitis without leukopenia, in 19%. Thrombocytopenia was seen in 19% of the patients, but was never a dose limiting factor alone. Leukopenia always preceded thrombocytopenia. The nadir for haematologic toxicity varied considerably between day 5-15 and 9-14 for leukocytes and platelets, respectively, while oral ulcerations, when they occurred, consistently began between days 3-6 after drug administration. Other toxic manifestations included dermatologic changes in 8 patients, hepatic dysfunction in 7, conjunctivitis in 7, nausea and vomiting in 6, alopecia in 4, and diarrhea in 3 patients.

The only factor which predicted toxicity was the patient's age. Drug tolerance was independent of previous chemotherapy or radiotherapy, weight loss, serum albumin or pretreatment serum folic acid levels.

Full text

PDF
302

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BERTINO J. R., DONOHUE D. R., GABRIO B. W., SILBER R., ALENTY A., MEYER M., HUENNEKENS F. M. Increased level of dihydrofolic reductase in leucocytes of patients treated with amethopterin. Nature. 1962 Jan 13;193:140–142. doi: 10.1038/193140a0. [DOI] [PubMed] [Google Scholar]
  2. BERTINO J. R. THE MECHANISM OF ACTION OF THE FOLATE ANTAGONISTS IN MAN. Cancer Res. 1963 Sep;23:1286–1306. [PubMed] [Google Scholar]
  3. Bertino J. R., Donohue D. M., Simmons B., Gabrio B. W., Silber R., Huennekens F. M. THE "INDUCTION" OF DIHYDROFOLIC REDUCTASE ACTIVITY IN LEUKOCYTES AND ERYTHROCYTES OF PATIENTS TREATED WITH AMETHOPTERIN. J Clin Invest. 1963 Apr;42(4):466–475. doi: 10.1172/JCI104735. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. CONDIT P. T., BERLIN N. I., NATHAN D. G. Studies on the folic acid vitamins. VI. The effect of amethopterin on erythropoiesis in man. Cancer. 1960 Mar-Apr;13:245–249. doi: 10.1002/1097-0142(196003/04)13:2<245::aid-cncr2820130207>3.0.co;2-n. [DOI] [PubMed] [Google Scholar]
  5. CONDIT P. T., SHNIDER B. I., OWENS A. H., Jr Studies on the folic acid vitamins. VII. The effects of large doses of amethopterin in patients with cancer. Cancer Res. 1962 Jul;22:706–712. [PubMed] [Google Scholar]
  6. CONDIT P. T. Studies on the folic acid vitamins. II. The acute toxicity of amethopterin in man. Cancer. 1960 Mar-Apr;13:222–228. doi: 10.1002/1097-0142(196003/04)13:2<222::aid-cncr2820130203>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  7. Capizzi R. L., DeConti R. C., Marsh J. C., Bertino J. R. Methotrexate therapy of head and neck cancer: improvement in therapeutic index by the use of leucovorin "rescue". Cancer Res. 1970 Jun;30(6):1782–1788. [PubMed] [Google Scholar]
  8. GOLDIN A., HUMPHREYS S. R., MANTEL N., VENDITTI J. M. Modification of treatment of schedules in the management of advanced mouse leukemia with amethopterin. J Natl Cancer Inst. 1956 Aug;17(2):203–212. [PubMed] [Google Scholar]
  9. GROSSOWICZ N., MANDELBAUM-SHAVIT F., DAVIDOFF R., ARONOVITCH J. Microbiologic determination of folic acid derivatives in blood. Blood. 1962 Nov;20:609–616. [PubMed] [Google Scholar]
  10. Gottlieb J. A., Serpick A. A. Prolonged intravenous methotrexate therapy in the treatment of acute leukemia and solid tumors. Cancer Res. 1970 Aug;30(8):2132–2138. [PubMed] [Google Scholar]
  11. Hersh E. M., Wong V. G., Henderson E. S., Freireich E. J. Hepatotoxic effects of methotrexate. Cancer. 1966 Apr;19(4):600–606. doi: 10.1002/1097-0142(196604)19:4<600::aid-cncr2820190420>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  12. Lane M., Moore J. E., 3rd, Levin H., Smith F. E. Methotrexate therapy for squamous cell carcinomas of the head and neck. Intermittent intravenous dose program. JAMA. 1968 May 13;204(7):561–564. [PubMed] [Google Scholar]
  13. Liegler D. G., Henderson E. S., Hahn M. A., Oliverio V. T. The effect of organic acids on renal clearance of methotrexate in man. Clin Pharmacol Ther. 1969 Nov-Dec;10(6):849–857. doi: 10.1002/cpt1969106849. [DOI] [PubMed] [Google Scholar]
  14. Magnus E. M. Folate activity in serum and red cells of patients with cancer. Cancer Res. 1967 Mar;27(3):490–497. [PubMed] [Google Scholar]
  15. Mitchell M. S., Wawro N. W., DeConti R. C., Kaplan S. R., Papac R., Bertino J. R. Effectiveness of high-dose infusions of methotrexate followed by leucovorin in carcinoma of the head and neck. Cancer Res. 1968 Jun;28(6):1088–1094. [PubMed] [Google Scholar]
  16. Ojima Y., Anderson L. L., Collins G. J., Oberfield R. A., Sullivan R. D. Pharmacologic studies of methotrexate in cancer patients with uropathy. Arch Surg. 1970 Feb;100(2):173–177. doi: 10.1001/archsurg.1970.01340200061014. [DOI] [PubMed] [Google Scholar]
  18. RAO P. B., LAGERLOEF B., EINHORN J., REIZENSTEIN P. G. FOLIC ACID ACTIVITY IN LEUKEMIA AND CANCER. Cancer Res. 1965 Feb;25:221–224. [PubMed] [Google Scholar]
  19. Schabel F. M., Jr The use of tumor growth kinetics in planning "curative" chemotherapy of advanced solid tumors. Cancer Res. 1969 Dec;29(12):2384–2389. [PubMed] [Google Scholar]
  20. Schwarzenberg L., Mathé G., Hayat M., de Vassal F., Amiel J. L., Cattan A., Schneider M., Schlumberger J. R., Rosenfeld C., Jasmin C. Une nouvelle combinaison de méthotrexate et d'acide folnique pour le traitement des cancers. (Leucémies aiguës et tumeurs solides) Presse Med. 1969 Mar 1;77(11):385–388. [PubMed] [Google Scholar]
  21. WERKHEISER W. C. The relation of folic acid reductase to aminopterin toxicity. J Pharmacol Exp Ther. 1962 Aug;137:167–172. [PubMed] [Google Scholar]
  22. Zaharko D. S., Bruckner H., Oliverio V. T. Antibiotics alter methotrexate metabolism and excretion. Science. 1969 Nov 14;166(3907):887–888. doi: 10.1126/science.166.3907.887. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES